Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | KMO | O15229 | 1/20 | 0.51 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.51 |
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.50 |
| ▸ | MKNK2 | Q9HBH9 | 3/20 | 0.50 |
| ▸ | SYK | P43405 | 1/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.46 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.46 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.46 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | HNF4A | P41235 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29917759 | 0.86 | GPR35 (0.48) | HTTKDM4ELMNAKMOGPR35 | |
| SCHEMBL6237458 | 0.86 | MKNK1 (0.58) | LMNAMKNK1MKNK2CYP3A4CYP2C19 | |
| SCHEMBL27894364 | 0.83 | MKNK1 (0.56) | HTTKDM4ELMNAGPR35MKNK1 | |
| SCHEMBL15830641 | 0.83 | KMT2A (0.53) | KDM4EMKNK1MKNK2KMT2AALDH1A1 | |
| SCHEMBL29504659 | 0.83 | HTT (0.56) | HTTKDM4ELMNAKMOMKNK1 | |
| SCHEMBL30335331 | 0.83 | HTT (0.56) | HTTKDM4ELMNAKMOMKNK1 | |
| SCHEMBL1173860 | 0.83 | HTT (0.56) | HTTKDM4ELMNAKMOMKNK1 | |
| SCHEMBL121422 | 0.83 | HNF4A (0.63) | KDM4ELMNACYP3A4CYP2C9HNF4A | |
| SCHEMBL28830427 | 0.82 | KMO (0.53) | HTTKDM4ELMNAKMOGPR35 | |
| SCHEMBL27845475 | 0.82 | KMO (0.53) | HTTKDM4ELMNAKMOGPR35 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111978200-B | Biphenylamide derivative, preparation method and application | 湖北省生物农药工程研究中心 | 2022-09-13 | — | — | CN | disclosed |
| CN-111978200-A | Bibenzamide derivative and preparation method and application thereof | 湖北省生物农药工程研究中心 | 2020-11-24 | — | — | CN | disclosed |
| US-6979693-B2 | Pyrazole derivatives-p38 MAP kinase inhibitors | SYNTEX (U.S.A.) LLC (US) | 2005-12-27 | — | — | US | disclosed |
| EP-1075467-B1 | PYRAZOLE DERIVATIVES AS P-38 MAP KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2005-03-30 | — | — | EP | disclosed |
| US-20030018051-A1 | Pyrazole derivatives - p38 MAP kinase inhibitors | GOLDSTEIN DAVID MICHAEL (US) | 2003-01-23 | — | — | US | disclosed |
| US-20020156114-A1 | Pyrazole derivatives - p38 MAP kinase inhibitors | GOLDSTEIN DAVID MICHAEL (US) | 2002-10-24 | — | — | US | disclosed |
| US-6444696-B1 | 1-ARYL OR HETEROARYL SUBSTITUTED 5-AMINO-4 CARBONYLPYRAZOLE DERIVATIVES; ANTIINFLAMMATORY AGENTS | SYNTEX (U.S.A.) LLC | 2002-09-03 | — | — | US | disclosed |
| US-20020103245-A1 | Pyrazole derivatives P38 MAP kinase inhibitors | GOLDSTEIN DAVID MICHAEL (US) | 2002-08-01 | — | — | US | disclosed |
| EP-1218346-A1 | PYRAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-07-03 | — | — | EP | disclosed |
| US-6376527-B1 | ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASES | SYNTEX (U.S.A.) LLC | 2002-04-23 | — | — | US | disclosed |
| US-6316466-B1 | Pyrazole derivatives P-38 MAP kinase inhibitors | SYNTEX (U.S.A.) LLC | 2001-11-13 | — | — | US | disclosed |
| WO-2001021591-A1 | PYRAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2001-03-29 | — | — | WO | disclosed |
| EP-1075467-A1 | PYRAZOLE DERIVATIVES AS P-38 MAP KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-02-14 | — | — | EP | disclosed |
| WO-1999057101-A1 | PYRAZOLE DERIVATIVES AS P-38 MAP KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 1999-11-11 | — | — | WO | disclosed |
| US-4937346-A | Phenyl-azacykloalkanes | Carlsson, Per Arvid Emil (SE) | 1990-06-26 | — | — | US | disclosed |
| US-4719219-A | Phenyl-azacycloalkanes and use thereof in treatment of central nervous system disorders | Carlsson, Per A. E. (SE) | 1988-01-12 | — | — | US | disclosed |
| US-4426386-A | CNS DISORDERS | ASTRA LAKEMEDEL AKTIEBOLAG (SE) | 1984-01-17 | — | — | US | disclosed |
| EP-0084920-A2 | New compounds useful as intermediates or starting materials for preparation of therapeutically useful phenyl-azacycloalkanes | Carlsson, Per Arvid Emil (SE) | 1983-08-03 | — | — | EP | disclosed |
| EP-0030526-A1 | New phenyl-azacycloalkanes, processes for preparation and pharmaceutical preparations for such compounds | Astra Läkemedel Aktiebolag (SE) | 1981-06-17 | — | — | EP | disclosed |
| WO-1981001552-A1 | NEW PHENYL-AZACYCLOALKANES | ASTRA LAEKEMEDEL AB (SE) | 1981-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018051-A1 | Pyrazole derivatives - p38 MAP kinase inhibitors | MAPK1, MAPK8, MAP3K8 | HTT 4759/4885KDM4E 4214/4885LMNA 1840/4885 |
| US-20020103245-A1 | Pyrazole derivatives P38 MAP kinase inhibitors | MAPK1, MAPK8, MAPKAPK2 | HTT 4746/4885KDM4E 4148/4885LMNA 2094/4885 |
| US-20020156114-A1 | Pyrazole derivatives - p38 MAP kinase inhibitors | MAPK1, MAPK8, MAP3K8 | HTT 4759/4885KDM4E 4214/4885LMNA 1840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.